文献速递头颈外科

蓝莓提取物在头颈癌临床前模型中具有抗增殖活性

Blueberry Extract Has Anti-Proliferative Activity in Preclinical Models of Head and Neck Cancer.
PubMed 文献 · Head Neck · 2026-09-06

该研究利用多种免疫健全小鼠口腔癌模型,探讨蓝莓提取物(BE)对肿瘤控制及抗肿瘤免疫的影响。结果显示,BE饮水可显著延缓肿瘤生长,与抗PD-1免疫治疗联用在一个模型中常致肿瘤排斥;BE主要经非免疫抗氧化机制发挥作用,在4-NQO癌变模型中化学预防活性有限,在模拟微小残留病灶模型中无明显获益。结论提示BE或可作为HNSCC标准治疗的辅助手段,早期癌变阶段效用有限,肿瘤进展后期更有效。

要点

  • 蓝莓提取物饮水可显著延缓免疫健全小鼠口腔癌生长。
  • 与抗PD-1联用在一个模型中常致肿瘤排斥。
  • BE主要经非免疫抗氧化机制发挥作用,早期癌变阶段效用有限。

核心结论

  • 蓝莓提取物可能作为HNSCC标准治疗的辅助手段,早期肿瘤发生阶段效用有限,肿瘤进展后期更有效。

研究设计与样本

  • 研究采用多种免疫健全小鼠口腔癌模型,探索蓝莓提取物对肿瘤控制和抗肿瘤免疫应答的影响。

主要发现

  • BE加入饮水可显著延缓肿瘤生长,在一个模型中与抗PD-1免疫治疗联用常致肿瘤排斥。
  • 肿瘤免疫谱分析、RNA测序和细胞耗竭研究提示BE主要经非免疫抗氧化机制发挥作用。
  • 在4-NQO癌变模型中BE作为化学预防策略活性有限,在模拟微小残留病灶模型中无明显获益。

临床怎么用

  • 临床前证据提示BE或可作为HNSCC标准治疗的辅助手段,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Head and neck squamous cell carcinoma (HNSCC) arises from premalignant lesions and has a high rate of disease relapse. Novel therapies are needed to treat established tumors and prevent progression of premalignant lesions. METHODS: Multiple immunocompetent murine models of oral cancer were used to explore the effects of blueberry extract (BE) on tumor control and anti-tumor immune responses. RESULTS: BE added to drinking water provided robust tumor growth delay, resulting in frequent tumor rejection when combined with anti-PD-1 immunotherapy in one model. Tumor immune profiling, RNA sequencing, and cell depletion studies suggest that BE acts primarily via non-immune, antioxidant mechanisms. When given to mice in the 4-NQO carcinogenesis model, BE showed modest activity as a chemoprevention strategy; in a model mimicking minimal residual disease, BE showed no appreciable benefit. CONCLUSIONS: These findings suggest that BE may have some utility as an adjunct to standard therapies for HNSCC, with limited utility during early tumorigenesis but more efficacy at later stages of tumor progression.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Kinney BLC, Lubin D, Kansal V, et al. Blueberry Extract Has Anti-Proliferative Activity in Preclinical Models of Head and Neck Cancer. Head Neck. 2026. PMID: 42702937. doi:10.1002/hed.70466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。